A novel approach to stabilize fetal cell-free DNA fraction in maternal blood samples for extended period of time

This study was undertaken to evaluate a novel method for stabilizing and preserving the original proportion of cell-free fetal DNA (cffDNA) in maternal blood for extended periods of time without using crosslinking agents, such as formaldehyde, which compromise DNA integrity and extraction efficiency...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 13; no. 12; p. e0208508
Main Authors Fernando, M Rohan, Jiang, Chao, Krzyzanowski, Gary D, Somer-Shely, Tifany, Ryan, Wayne L
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 06.12.2018
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study was undertaken to evaluate a novel method for stabilizing and preserving the original proportion of cell-free fetal DNA (cffDNA) in maternal blood for extended periods of time without using crosslinking agents, such as formaldehyde, which compromise DNA integrity and extraction efficiency. Blood was drawn from pregnant donors into K3EDTA and Blood Exo DNA ProTeck® (ProTeck) tubes. Blood drawn into both tubes were aliquoted and stored at three different temperatures. At indicated times sample aliquots were processed for cell-free DNA (cfDNA) extraction. Plasma cfDNA and cffDNA quantified by droplet digital PCR (ddPCR) assay which amplify RASSF1A gene promoter region. ProTeck reagent is formaldehyde free and inhibits blood cell metabolism in blood samples during storage. Cell-free DNA concentration increased over time in blood plasma stored in K3EDTA tubes at 4, 22 and 30°C. Blood stored in ProTeck tubes, cfDNA concentration was stable at 4, 22 and 30°C for 21, 28 and 7 days, respectively. In K3EDTA tubes cffDNA proportion decreases steadily over time whereas in ProTeck tubes cffDNA proportion remained stable. This novel technology stabilizes cffDNA proportion in maternal blood samples at 4, 22 and 30°C for 21, 28 and 7 days, respectively.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors of this manuscript, MRF, GDK and CJ are all full time employees of the University of Nebraska Medical Center, Department of Obstetrics and Gynecology, Omaha NE USA. WLR is Professor Emeritus, University of Nebraska Medical Center, who has been associated with the department for more than 40 years. WLR passed away November 03, 2017. TS-S is a full time employee of Methodist Women’s Hospital, Omaha NE USA. CJ and TS-S has no conflicts of interest. MRF, GDK and WLR started CFGenome, a startup company based in Omaha NE USA. MRF and GDK are shareholders of CFGenome. MRF applied for patent for work described in this manuscript (Inventor: M Rohan Fernando Applicant: CFGenome LLC: A chemical composition to stabilize extracellular vesicles in a blood sample and methods of use thereof: WO 2017/214310 A1). This does not alter our adherence to PLOS ONE policies on sharing data and material.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0208508